Neuroradiology

, Volume 45, Issue 6, pp 393–399 | Cite as

MR diffusion imaging and MR spectroscopy of maple syrup urine disease during acute metabolic decompensation

  • Wajanat Jan
  • Robert A. Zimmerman
  • Zhiyue J. Wang
  • Gerard T. Berry
  • Paige B. Kaplan
  • Edward M. Kaye
Diagnostic Neuroradiology

Abstract

Maple syrup urine disease (MSUD) is an inborn error of amino acid metabolism, which affects the brain tissue resulting in impairment or death if untreated. Imaging studies have shown reversible brain edema during acute metabolic decompensation. The purpose of this paper is to describe the diffusion-weighted imaging (DWI) and spectroscopy findings during metabolic decompensation and to assess the value of these findings in the prediction of patient outcome. Six patients with the diagnosis of MSUD underwent conventional MR imaging with DWI during acute presentation with metabolic decompensation. Spectroscopy with long TE was performed in four of the six patients. Follow-up examinations were performed after clinical and metabolic recovery. DWI demonstrated marked restriction of proton diffusion compatible with cytotoxic or intramyelinic sheath edema in the brainstem, basal ganglia, thalami, cerebellar and periventricular white matter and the cerebral cortex. This was accompanied by the presence of an abnormal branched-chain amino acids (BCAA) and branched-chain alpha-keto acids (BCKA) peak at 0.9 ppm as well as elevated lactate on proton spectroscopy in all four patients. The changes in all six patients were reversed with treatment without evidence of volume loss or persistent tissue damage. The presence of cytotoxic or intramyelinic edema as evidenced by restricted water diffusion on DWI, with the presence of lactate on spectroscopy, could imply imminent cell death. However, in the context of metabolic decompensation in MSUD, it appears that changes in cell osmolarity and metabolism can reverse completely after metabolic correction.

Keywords

Brain, edema Brain, diseases Magnetic resonance, diffusion study Magnetic resonance, spectroscopy Metabolism 

References

  1. 1.
    Chuang DT, Shih VE (2001) Maple syrup urine disease (branched-chain ketoaciduria). In: Scriver, Beaudet, Valle, et al (eds) The metabolic and molecular bases of inherited disease, 8th edn. McGraw-Hill, New York, pp 1971–2005Google Scholar
  2. 2.
    Rezvani I, Auerbach VH (1987) Defects in metabolism of amino acids. In: Behrman RE, Vaughan VC (eds) Nelson's textbook of pediatrics, 13th edn. WB Saunders, Philadelphia, pp 289–291Google Scholar
  3. 3.
    Brismar J, Aqeel A, Brismar G, Coates R, Gascon G, Ozand P (1990) Maple syrup urine disease: findings on CT and MR scans of the brain in 10 infants. AJNR Am J Neuroradiol 11: 1219–1228PubMedGoogle Scholar
  4. 4.
    Fariello G, Dionisi-Vici C, Orazi C, et al (1996) Cranial ultrasonography in maple syrup urine disease. AJNR Am J Neuroradiol 17: 311–315Google Scholar
  5. 5.
    Mikati MA, Dudin GE, Kaloustian VMD, Benson PF, Fensom AH (1982) Maple syrup urine disease with increased intracranial pressure. Am J Dis Child 136: 642–643PubMedGoogle Scholar
  6. 6.
    Backhouse O, Leitch RJ, Thompson D, et al (1999) A case of reversible blindness in maple syrup urine disease. Br J Ophthalmol 83: 250–251Google Scholar
  7. 7.
    Muller K, Kahn T, Wendel U (1993) Is demyelination a feature of maple syrup urine disease? Pediatr Neurol 9: 375–382Google Scholar
  8. 8.
    Martin JJ, Schlote W (1972) Central nervous system lesions in disorders of amino-acid metabolism. A neuropathological study. J Neurol Sci 15: 49–76CrossRefGoogle Scholar
  9. 9.
    Kandall BE (1992) Disorders of lysosomes, peroxisomes, and mitochondria. AJNR Am J Neuroradiol 13: 621–653PubMedGoogle Scholar
  10. 10.
    Harper PAW, Helay PJ, Dennis JA (1990) Animal model of human disease. Maple syrup urine disease (branched chain ketoaciduria). Am J Pathol 136: 1445–1447PubMedGoogle Scholar
  11. 11.
    Jouvet P, Rustin P, Felderhoff U, et al (1998) Maple syrup urine disease metabolites induce apoptosis in neural cells without cytochrome c release or changes in mitochondrial membrane potential. Biochem Soc Trans 26: S341Google Scholar
  12. 12.
    Vexler ZS, Roberts TP, Bollen AW, Derugin N, Arieff AI (1997) Transients cerebral ischemia. Association of apoptosis induction hypoperfusion. J Clin Invest 99: 1453–1459PubMedGoogle Scholar
  13. 13.
    Rumpel H, Ferrini B, Martin E (1998) Lasting cytotoxic edema as an indicator of irreversible brain damage: a case of neonatal stroke. AJNR Am J Neuroradiol 19: 1636–1638PubMedGoogle Scholar
  14. 14.
    Phillips MD, Zimmerman RA (1999) Diffusion imaging in pediatric hypoxic-ischemic injury. Neuroimaging Clin North Am 9: 41–52Google Scholar
  15. 15.
    Albers GW (1998) Diffusion-weighted MRI for evaluation of acute stroke. Neurology 51: S47–49PubMedGoogle Scholar
  16. 16.
    Zimmerman RA (2000) Pediatric cerebrovascular disease. JBR-BTR 83: 245–252Google Scholar
  17. 17.
    Forbes KPN, Pipe JG, Heiserman JE (2001) Evidence for cytotoxic edema in the pathogenesis of cerebral venous infarction. AJNR Am J Neuroradiol 22: 450–455PubMedGoogle Scholar
  18. 18.
    Tsuchiya K, Katase S, Yoshino A, Hachiya J (1999) Diffusion-weighted MR imaging of encephalitis. AJR Am J Roentgenol 173: 1097–1099PubMedGoogle Scholar
  19. 19.
    Tsuchiya K, Katase S, Yoshino A, Hachiya J (2000) MRI of influenza encephalopathy in children: value of diffusion-weighted imaging. J Comput Assist Tomogr 24: 303–307CrossRefPubMedGoogle Scholar
  20. 20.
    Yoneda M, Maeda M, Kimura H, Fujii A, Katayama K, Kuriyama M (1999) Vasogenic edema on MELAS: a serial study with diffusion-weighted MR imaging. Neurology 53: 2182–2184PubMedGoogle Scholar
  21. 21.
    Ohshita T, Oka M, Iman Y, et al (2000) Serial diffusion-weighted imaging in MELAS. Neuroradiology 42: 651–656CrossRefPubMedGoogle Scholar
  22. 22.
    Schaefer PW, Buonanno F, Gonzales RG, Schwamm LH (1997) Diffusion-weighted imaging discriminates between cytotoxic and vasogenic edema in a patient with eclampsia. Stroke 28: 1082–1085PubMedGoogle Scholar
  23. 23.
    Schwartz RB, Mulkern RV, Gudbjartsson H, Jolesz F (1998) Diffusion-weighted MR imaging in hypertensive encephalopathy: clues to pathogenesis. AJNR Am J Neuroradiol 19: 859–862PubMedGoogle Scholar
  24. 24.
    Felber SR, Sperl W, Chemelli A, Murr C, Wendel U (1993) Maple syrup urine disease: metabolic decompensation monitored by proton magnetic resonance imaging and spectroscopy. Ann Neurol 33: 396–401PubMedGoogle Scholar
  25. 25.
    Heindel W, Kugel H, Wendel U, Roth B, Benz-Bohm G (1995) Proton magnetic resonance spectroscopy reflects metabolic decompensation in maple syrup urine disease. Pediatr Radiol 25: 296–299PubMedGoogle Scholar
  26. 26.
    Wang ZJ, Zimmerman RA (1998) Proton MR spectroscopy of pediatric brain metabolic disorders. Neuroimaging Clin North Am 8: 781–807Google Scholar
  27. 27.
    Wang ZJ, Zimmerman RA, Sauter R (1996) Proton MR spectroscopy of the brain: clinically useful information obtained in assessing CNS diseases in children. AJR Am J Roentgenol 167: 191–199PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  • Wajanat Jan
    • 1
    • 4
  • Robert A. Zimmerman
    • 1
    • 2
  • Zhiyue J. Wang
    • 1
    • 5
  • Gerard T. Berry
    • 3
    • 6
  • Paige B. Kaplan
    • 3
  • Edward M. Kaye
    • 3
    • 7
  1. 1.Department of RadiologyUniversity of Pennsylvania School of Medicine, The Children's Hospital of PhiladelphiaPhiladelphiaUSA
  2. 2.Department of RadiologyChildren's Hospital of PhiladelphiaPhiladelphiaUSA
  3. 3.Department of PediatricsUniversity of Pennsylvania School of Medicine, The Children's Hospital of PhiladelphiaPhiladelphiaUSA
  4. 4.Guy's HospitalLondonUK
  5. 5.Texas Children's HospitalHoustonUSA
  6. 6.Children's National Medical CenterWashingtonUSA
  7. 7.Genzyme CorporationCambridgeUSA

Personalised recommendations